Delivery Order SPE2DB22D3501-SPE2DB25FVK06
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 18, 2025, for the supply of RINVOQ ER 15 mg tablets (30-count units) valued at $12,074.99. This is a firm fixed price, non-set-aside competitive delivery order with an ultimate completion date of November 19, 2025, and performance at the vendor's Conshohocken, Pennsylvania facility. This delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of RINVOQ ER 15 mg tablets in a quantity of 30 units, with a ceiling value of $6,888.58. This is a firm fixed-price delivery order with an ultimate completion date of September 29, 2025, and carries no set-aside designation, indicating it was competitively awarded. The place of performance is listed as Conshohocken, Pennsylvania, which is also the location of...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 18, 2025, for supply of RINVOQ ER 15 mg tablets (30-count unit dose) with a ceiling value of $9,492.44. This non-set-aside, competitively awarded delivery order utilizes firm fixed pricing and carries an ultimate completion date of November 19, 2025. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of RINVOQ ER 30 mg tablets in quantities of 30 units. The contract is valued at $11,191.56 with a firm fixed price structure and carries an ultimate completion date of August 22, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 24, 2025, for the supply of RINVOQ ER 30 mg tablets in quantities of 30s, with a contract ceiling value of $24,269.37. This is a firm fixed price delivery order with an ultimate completion date of October 27, 2025, and represents a non-competitive set-aside award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of RINVOQ ER 15 mg tablets in quantities of 30 units. This is a firm fixed price delivery order with a ceiling value of $16,761.64 and an ultimate completion date of July 25, 2025. The contract was competitively awarded without any set-aside designation, and performance will take place at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of RINVOQ ER 15 mg tablets in a quantity of 30 units. This competitively awarded, non-set-aside delivery order carries a ceiling value of $15,519.48 under firm fixed price terms, with an ultimate completion date of August 26, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) with a ceiling value of $6,558.40. Issued on November 14, 2025, with an ultimate completion date of November 17, 2025, this firm fixed-price delivery order represents a competitively awarded, non-set-aside procurement. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of RINVOQ ER 15 mg tablets (30-count units) valued at $37,258.50. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award through open procurement. The contract is set to conclude on September 17, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. RINVOQ is a JAK...
- The Defense Logistics Agency awarded a delivery order valued at $5,846.07 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on August 21, 2025, with a completion date of August 22, 2025. This is a firm fixed price, competitively awarded delivery order with no set-aside designation, to be performed at the contractor's Conshohocken, Pennsylvania location. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- SPE2DB22D3501Indefinite Delivery Contract
- SPE2DB22D3501-SPE2DB25FVK06Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on April 22, 2025, for the supply of RINVOQ ER 15 MG tablets in a quantity of 30 units. The contract is valued at $6,223.32 and represents a firm fixed price delivery order with an ultimate completion date of April 23, 2025. This award was made without a set-aside designation, indicating competitive procurement. The vendor will perform delivery from its corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999 and extends through December 2026. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving federal medical procurement needs across the Defense Logistics Agency's Medical Supply Chain. The company maintains an extensive portfolio of pharmaceutical product deliveries through competitively awarded contracts with firm fixed pricing structures. RINVOQ ER (upadacitinib extended-release) is a Janus kinase inhibitor used to treat rheumatoid arthritis and other inflammatory conditions, reflecting the company's role in supplying specialty medications to support military healthcare programs and other government healthcare systems worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.2k | 4/22/25 |